192 related articles for article (PubMed ID: 19331595)
41. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
42. Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Hosoe H; Kaise T; Ohmori K
J Pharmacol Toxicol Methods; 1998 Oct; 40(3):165-71. PubMed ID: 10334633
[TBL] [Abstract][Full Text] [Related]
43. The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
Demiralay R; Gürsan N; Erdem H
Toxicology; 2006 Feb; 219(1-3):197-207. PubMed ID: 16377052
[TBL] [Abstract][Full Text] [Related]
44. The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats.
Selcoki Y; Uz E; Bayrak R; Sahin S; Kaya A; Uz B; Karanfil A; Ozkara A; Akcay A
Toxicology; 2007 Sep; 239(1-2):53-9. PubMed ID: 17689165
[TBL] [Abstract][Full Text] [Related]
45. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
46. The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation.
Fraňová S; Kazimierová I; Pappová L; Molitorisová M; Jošková M; Šutovská M
Pulm Pharmacol Ther; 2019 Feb; 54():60-67. PubMed ID: 30502381
[TBL] [Abstract][Full Text] [Related]
47. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease.
Moretti M
Expert Rev Respir Med; 2007 Dec; 1(3):307-16. PubMed ID: 20477170
[TBL] [Abstract][Full Text] [Related]
48. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents.
Poole PJ; Black PN
Am J Respir Med; 2003; 2(5):367-70. PubMed ID: 14719989
[TBL] [Abstract][Full Text] [Related]
49. Antioxidant effect of erdosteine and lipoic acid in ovarian ischemia-reperfusion injury.
Dokuyucu R; Karateke A; Gokce H; Kurt RK; Ozcan O; Ozturk S; Tas ZA; Karateke F; Duru M
Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():23-7. PubMed ID: 25461347
[TBL] [Abstract][Full Text] [Related]
50. Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial.
Chang AB; Yerkovich ST; Baines KJ; Burr L; Champion A; Chatfield MD; Eg KP; Goyal V; Marsh RL; McCallum GB; McElrea M; McPhail S; Morgan LC; Morris PS; Nathan AM; O'Farrell H; Sanchez MO; Parsons M; Schultz A; Torzillo PJ; West NP; Versteegh L; Marchant JM; Grimwood K
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38719503
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.
Unuvar E; Tamay Z; Yildiz I; Toprak S; Kilic A; Aydin S; Kilic G; Guler N; Oguz F; Sidal M
Acta Paediatr; 2010 Apr; 99(4):585-9. PubMed ID: 20055782
[TBL] [Abstract][Full Text] [Related]
52. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice.
Hayashi K; Hosoe H; Kaise T; Ohmori K
J Pharm Pharmacol; 2000 Nov; 52(11):1411-6. PubMed ID: 11186250
[TBL] [Abstract][Full Text] [Related]
53. Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction.
Sener G; Sehirli AO; Toklu HZ; Yuksel M; Ercan F; Gedik N
Pediatr Surg Int; 2007 Mar; 23(3):233-41. PubMed ID: 17216233
[TBL] [Abstract][Full Text] [Related]
54. [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin].
Erden ES; Kirkil G; Deveci F; Ilhan N; Cobanoğlu B; Turgut T; Muz MH
Tuberk Toraks; 2008; 56(2):127-38. PubMed ID: 18701972
[TBL] [Abstract][Full Text] [Related]
55. Erdosteine prevents colonic inflammation through its antioxidant and free radical scavenging activities.
Sener G; Aksoy H; Sehirli O; Yüksel M; Aral C; Gedik N; Cetinel S; Yeğen BC
Dig Dis Sci; 2007 Sep; 52(9):2122-32. PubMed ID: 17431768
[TBL] [Abstract][Full Text] [Related]
56. Mucoactive and antioxidant medicines for COPD: consensus of a group of Chinese pulmonary physicians.
Yan X; Song Y; Shen C; Xu W; Chen L; Zhang J; Liu H; Huang M; Lai G; Qian G; Wang J; Ye X; Zheng J; Bai C
Int J Chron Obstruct Pulmon Dis; 2017; 12():803-812. PubMed ID: 28405161
[TBL] [Abstract][Full Text] [Related]
57. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
[TBL] [Abstract][Full Text] [Related]
58. [Effects of mucolytic agents and macrolides in the treatment of COPD].
Yamaya M
Nihon Rinsho; 2016 May; 74(5):833-8. PubMed ID: 27254955
[TBL] [Abstract][Full Text] [Related]
59. [Effects of erdosteine on inflammation and fibrosis in rats with pulmonary fibrosis induced by bleomycin].
Karapolat S
Tuberk Toraks; 2009; 57(2):244-5; author reply 245-6. PubMed ID: 19714520
[No Abstract] [Full Text] [Related]
60. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.
Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
Trends Pharmacol Sci; 2019 Jul; 40(7):452-463. PubMed ID: 31147200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
